Practice Insights
2025/10/21
Understanding Your Labor Rights in Taiwan as a Foreign Employee
Foreign professionals working in Taiwan should be aware of their basic labor rights. A written employment contract is essential — it should clearly state your job duties, working hours, salary, leave entitlements, and termination conditions. If your contract is only in Chinese, consider getting a professional translation.
2025/10/21
AT&T and Nokia Win Patent Infringement Lawsuit
In August 2021, Finesse Wireless LLC filed a lawsuit against AT&T Mobility in the U.S. District Court for the Eastern District of Texas, alleging that AT&T had infringed two patents related to reducing wireless signal interference. Nokia, which designed and manufactured the base stations used in AT&T’s network, intervened in the case and contested Finesse’s claims, arguing that its equipment did not infringe the asserted patents.
2025/10/21
FDA Approves the World’s First PDE4B Inhibitor Nerandomilast for Idiopathic Pulmonary Fibrosis
On October 7, 2025, the U.S. Food and Drug Administration (FDA) officially approved Boehringer Ingelheim’s oral tablet nerandomilast (brand name Jascayd) for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). This marks the first FDA approval of a new IPF therapy since nintedanib (Ofev) and pirfenidone (Esbriet) were approved in 2014, representing a major breakthrough after more than a decade of stagnation in this therapeutic field.
2025/10/21
UCB’s “Zilucoplan” has been approved for marketing in China
On October 11, 2025, UCB S.A. (hereinafter referred to as UCB) announced that the NMPA had approved the marketing authorization for Zilucoplan (brand name: ZHUOBEIKE®), which is used in combination with conventional therapeutic drugs for the treatment of adult generalized myasthenia gravis (gMG) patients with positive anti-acetylcholine receptor (AChR) antibodies.
2025/09/29
Novartis Atrasentan Hydrochloride Tablets Approved in China
Recently, Novartis announced that its innovative product Atrasentan Hydrochloride Tablets (Proprietary Name: VANRAFIA) has been approved by the National Medical Products Administration (NMPA) for reducing proteinuria in adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of rapid disease progression. This marks the first non-immunologic therapy for IgA nephropathy in China, and the only highly selective endothelin-A (ETA) receptor antagonist approved domestically, representing a milestone that may reshape the long-term management of the disease.
2025/09/29
xAI Wins Court Order Blocking Former Engineer from Sharing AI Technology with OpenAI
Elon Musk’s artificial intelligence startup xAI has filed a lawsuit against a former engineer, accusing him of misappropriating “cutting-edge AI technologies with features superior to those offered by ChatGPT” and using them in his new role at OpenAI. The engineer began working at xAI last year, where he helped train and develop the company’s chatbot, Grok.
2025/09/29
InnoCare’s “Orelabrutinib” has been approved in Singapore
On September 8, 2025, Beijing InnoCare Pharma Tech Co., Ltd. (hereinafter referred to as “InnoCare”) announced that Orelabrutinib (brand name: InnoKai®) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed/refractory marginal zone lymphoma (R/R MZL). This marks the second indication for Orelabrutinib approved in Singapore, representing a solid step forward for the company on its path to internationalization.
2025/09/16
NT$10,000 Cash Handouts: Are Foreigners Eligible?
On August 29, the Executive Yuan passed in third reading the Special Act for Strengthening Economic, Social and National Security Resilience in Response to International Circumstances (因應國際情勢強化經濟社會及國土安全韌性特別條例), set to counter the adverse economic impact of the U.S. President Donald Trump’s tariff plan on Taiwan.
2025/09/07
Lululemon Sues Costco Over Alleged Counterfeit Sales
In July 2025, Lululemon filed a lawsuit against Costco in the U.S. District Court for the Central District of California, alleging that Costco’s private label brand, Kirkland, is manufacturing and selling hoodies, jackets, and pants that closely resemble some of Lululemon’s popular products. The suit claims this causes consumer confusion, leading some to mistakenly believe that Kirkland products are made by the authentic supplier of the “original” products.
2025/09/07
SUN PHARMA LAUNCHES HAIR LOSS DRUG IN THE UNITED STATES AFTER PATENT DISPUTE SETTLEMENT WITH INCYTE
On July 14, 2025, Sun Pharmaceutical Industries Ltd. (“Sun Pharma”), a generic drug manufacturer based in Bombay, India, announced the settlement of a patent infringement lawsuit with US-based biopharmaceutical corporation Incyte Corporation (“Incyte”) related to its hair loss drug LEQSELVI and the subsequent launch of that drug in the United States for the treatment of adults with severe alopecia areata.